News / Canada / bnn_bloomberg
UBS Analyst Highlights Growth Potential in Teva, United Therapeutics and Acadia Pharmaceuticals
Health Technology · Biotechnology · bnn_bloomberg · 2026-09-16
TEVA, UTHR, ACAD
UBS analyst Ash Verma identifies three healthcare stocks with strong growth prospects, driven by innovation, clinical catalysts, and sector-wide M&A activity.
What Happened
Sector Outlook: The biotechnology and specialty pharmaceutical sectors are experiencing a resurgence in investor interest, supported by positive clinical data and a clearer regulatory environment. Analysts note that fundamental valuations remain attractive as large pharmaceutical companies increasingly turn to M&A to address looming patent cliffs.
Teva Pharmaceuticals Strategy: Teva is successfully pivoting from a traditional generics business toward high-value branded medicines, which are projected to comprise 40% of its revenue within five years. The company’s stabilized generics division currently provides robust free cash flow, funding its transition into more innovative R&D pipelines.
United Therapeutics Pipeline: United Therapeutics is positioned for growth through the upcoming launch of Tyvaso for idiopathic pulmonary fibrosis, a condition with significant unmet medical needs. Additionally, the company is pioneering advanced xenotransplantation technology, aiming to address critical organ shortages through innovative medical research.
Acadia Pharmaceuticals Catalyst: Acadia Pharmaceuticals presents a compelling risk-reward profile ahead of an imminent Phase 2 clinical readout for its Alzheimer’s disease psychosis treatment. The company maintains a stable, profitable core business, providing a valuation floor should the upcoming clinical data fail to meet expectations.